Q2 EPS Estimate for Bausch Health Cos Increased by Analyst

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Analysts at Zacks Research boosted their Q2 2026 EPS estimates for shares of Bausch Health Cos in a research note issued to investors on Monday, June 23rd. Zacks Research analyst R. Department now expects that the company will post earnings of $0.98 per share for the quarter, up from their prior forecast of $0.97. The consensus estimate for Bausch Health Cos' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos' Q3 2026 earnings at $1.14 EPS, FY2026 earnings at $4.12 EPS and Q1 2027 earnings at $1.10 EPS.

BHC has been the topic of a number of other research reports. Royal Bank Of Canada raised their target price on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Wall Street Zen cut Bausch Health Cos from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $7.42.

Bausch Health Cos Stock Performance

Bausch Health Cos stock opened at $6.38 on Thursday. Bausch Health Cos has a 52 week low of $3.96 and a 52 week high of $9.85. The firm has a market capitalization of $2.36 billion, a PE ratio of -58.00 and a beta of 0.28. The business's 50-day simple moving average is $5.09 and its 200-day simple moving average is $6.32.

Insider Activity at Bausch Health Cos

In other news, Director John Paulson acquired 754,134 shares of Bausch Health Cos stock in a transaction on Tuesday, June 10th. The stock was bought at an average price of $5.05 per share, for a total transaction of $3,808,376.70. Following the transaction, the director now owns 27,193,169 shares of the company's stock, valued at $137,325,503.45. The trade was a 2.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have bought 6,352,667 shares of company stock worth $35,870,767 over the last three months. Company insiders own 8.05% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Toronto Dominion Bank boosted its stake in Bausch Health Cos by 1.0% during the fourth quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock worth $1,350,000 after buying an additional 1,712 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Bausch Health Cos by 7.9% during the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after acquiring an additional 1,896 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Bausch Health Cos by 10.6% during the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock valued at $220,000 after acquiring an additional 2,600 shares in the last quarter. Blair William & Co. IL increased its stake in Bausch Health Cos by 3.2% in the fourth quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock valued at $683,000 after acquiring an additional 2,622 shares during the period. Finally, SBI Securities Co. Ltd. raised its position in Bausch Health Cos by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after purchasing an additional 3,001 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.